Artal Group S.A. Leap Therapeutics, Inc. Transaction History

Artal Group S.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	BUY	$1.35 - $4.01 $1.35 Million - $4.01 Million	1,000,000 Added 33.33%	4,000,000 $16 Million
Q4 2020 Feb 11, 2021	BUY	$1.49 - $2.37 $260,303 - $414,039	174,700 Added 6.18%	3,000,000 $6.75 Million
Q3 2020 Nov 13, 2020	SELL	$1.68 - $2.17 $249,816 - $322,679	-148,700 Reduced 5.0%	2,825,300 $5.59 Million
Q2 2020 Aug 14, 2020	BUY	$1.39 - $2.84 $3.79 Million - $7.74 Million	2,724,000 Added 1089.6%	2,974,000 $6.22 Million
Q1 2020 May 14, 2020	BUY	$1.06 - $2.94 $265,000 - $735,000	250,000 New	250,000 $395,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $344M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.